ClinicalTrials.gg
RecruitingNCT07690852Updated Oct 30, 2026

Environmental Exposure Assessment in High-Risk and Early-Onset Breast Cancer Care

An observational study in Breast Carcinoma, sponsored by City of Hope Medical Center. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by City of Hope Medical Center · Observational

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 30, 2026Primary completion movedStart date moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
423
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 89 studies in Breast Neoplasms by City of Hope Medical Center — 17 open to participants now, 39 under way, 1 of them phase 3. Breast Neoplasms · City of Hope Medical Center.

Planned enrollment
4th of 12
423 · median 219
Started
2026
with 4 others
Observational
12 of 89
2 open now
Primary completion
2029-02
later than 34 of 38 live
Registered
88th of 89
by date

Among the 89 studies in Breast Neoplasms by City of Hope Medical Center, this one is the 4th largest by planned enrollment of the 12 observational ones that give a count, is one of 5 that started in 2026, is one of 12 observational ones, reaches primary completion later than 34 of the 38 other live ones, and was the 88th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

17 of the 89 studies in Breast Neoplasms by City of Hope Medical Center are open now, in 1 country. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Breast Neoplasms by City of Hope Medical Center, or all of them as a file.
02

Study summary

This study evaluates patient and provider attitudes about environmental exposure risk assessments into clinical care for female patients at average or high risk for breast cancer and/or diagnosed with early onset breast cancer.

Read the detailed description

PRIMARY OBJECTIVES:

I. To assess patient interest and emotional responses toward EERA and return of results.

II. To assess provider attitudes toward EERA integration into clinical workflows.

OUTLINE: This is an observational study. Participants are assigned to 1 of 3 aims.

AIM I: Average and high risk breast cancer participants and early onset breast cancer patients complete a survey over 15-25 minutes and may attend an interview over 30-45 minutes. Participants' and patients' medical records are reviewed.

AIM II: COH providers complete a survey over 15-25 minutes and may attend an interview over 30-45 minutes.

AIM III: Average and high risk breast cancer participants complete a baseline survey over 15-25 minutes and wear Fresh Air Clip wristbands for 1 week. Participants then complete a follow up survey over 15-25 minutes and may attend an interview over 30-45 minutes. Participants' medical records are reviewed.

03

Conditions studied

  • Breast Carcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Female patients aged 18 years or older who either are considered average risk for developing breast cancer or high-risk for developing breast cancer or have early-onset breast cancer as well as providers at City of Hope.

Eligibility criteria

Inclusion Criteria:

  • AIM 1 INCLUSION CRITERIA:

    • ONE of the following:

      • Either average risk of developing breast cancer (defined by woman with no Tyrer-Cuzick model ≥ 20%, no mention of Tyrer-Cuzick model, and no Pathogenic/Likely Pathogenic [P/LP] in breast cancer related genes) OR high risk of developing breast cancer (defined by ≥ 20% chance of developing breast cancer across lifetime measured by Tyrer-Cuzick model or gene mutation carrier, P/LP carrier in breast cancer related genes including BRCA1, BRCA2, BARD1, ATM, CHEK2, CDH1, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53) OR early onset breast cancer (defined by a breast cancer diagnosis in a patient younger than 50 years of age)
    • Age: ≥ 18 years
    • Speak English or Spanish
    • Sex: female
    • Willingness to:

      • Participate in study activities
      • Permit medical record/ clinical laboratory result review
  • AIM 2 INCLUSION CRITERIA

    • Practice at COH (i.e., genetic counselors, geneticists, oncologists, nurse practitioners)
    • Willingness to:

      • Participate in study activities
  • AIM 3 INCLUSION CRITERIA:

    • Provide written consent
    • ONE of the following:

      • Either average risk of developing breast cancer (defined by woman with no Tyrer-Cuzick model ≥ 20%, no mention of Tyrer-Cuzick model, and no P/LP in breast cancer related genes) OR High risk: empirical risk of developing breast cancer (defined by ≥ 20% chance of developing breast cancer across lifetime measured by Tyrer-Cuzick model and no P/LP in breast cancer related genes) OR High Risk: gene carrier (defined by P/LP carrier in breast cancer related genes, including BRCA1, BRCA2, BARD1, ATM, CHEK2, CDH1, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53)
    • Age: ≥ 18 years
    • Speak English or Spanish
    • Sex: female
    • Willingness to:

      • Wear the wristband for 1 week
      • Participate in study activities
      • Permit medical record/ clinical laboratory result review
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
423 participants (estimated)

Groups and cohorts

  • Observational Aim I

    Average and high risk breast cancer participants and early onset breast cancer patients complete a survey over 15-25 minutes and may attend an interview over 30-45 minutes. Participants' and patients' medical records are reviewed.

    Other: Non-Interventional Study

  • Observational Aim II

    COH providers complete a survey over 15-25 minutes and may attend an interview over 30-45 minutes.

    Other: Non-Interventional Study

  • Observational Aim III

    Average and high risk breast cancer participants complete a baseline survey over 15-25 minutes and wear Fresh Air Clip wristbands for 1 week. Participants then complete a follow up survey over 15-25 minutes and may attend an interview over 30-45 minutes. Participants' medical records are reviewed.

    Other: Non-Interventional Study

Interventions

  • OtherNon-Interventional Study

    Non-interventional study

    Also known as: Non-Interventional Observational Study, Noninterventional (Observational) Study

06

What researchers measure

Primary outcomes

  1. Patient survey responses on perceived utility

    Will compare emotional responses, environmental health literacy, compensatory health behaviors, and cancer fatalism across the three participant groups (average risk, high risk, and early onset) using analysis of covariance (ANCOVA). Emotional response scores will be constructed by summing items within the positive and negative subscales separately, while the environmental health literacy, compensatory health behaviors and cancer fatalism will be calculated as summed total scores. ANCOVA will be used to estimate adjusted mean differences across groups and to evaluate whether post intervention responses differ after accounting for demographic factors. Interview sessions will be audio-recorded and transcribed verbatim.

    Time frame: Up to one year

  2. Patient survey responses on willingness to engage

    Will compare emotional responses, environmental health literacy, compensatory health behaviors, and cancer fatalism across the three participant groups (average risk, high risk, and early onset) using ANCOVA. Emotional response scores will be constructed by summing items within the positive and negative subscales separately, while the environmental health literacy, compensatory health behaviors and cancer fatalism will be calculated as summed total scores. ANCOVA will be used to estimate adjusted mean differences across groups and to evaluate whether post intervention responses differ after accounting for demographic factors. Interview sessions will be audio-recorded and transcribed verbatim.

    Time frame: Up to one year

  3. Patient survey responses on preferences for receiving EERA results

    Will compare emotional responses, environmental health literacy, compensatory health behaviors, and cancer fatalism across the three participant groups (average risk, high risk, and early onset) using ANCOVA. Emotional response scores will be constructed by summing items within the positive and negative subscales separately, while the environmental health literacy, compensatory health behaviors and cancer fatalism will be calculated as summed total scores. ANCOVA will be used to estimate adjusted mean differences across groups and to evaluate whether post intervention responses differ after accounting for demographic factors. Interview sessions will be audio-recorded and transcribed verbatim.

    Time frame: Up to one year

  4. Provider survey responses on perceived utility

    Descriptive analysis will be used to examine all quantitative variables.

    Time frame: Up to one year

  5. Provider survey responses on feasibility

    Descriptive analysis will be used to examine all quantitative variables.

    Time frame: Up to one year

  6. Provider survey responses on preferences for EERA disclosures into workflows

    Descriptive analysis will be used to examine all quantitative variables.

    Time frame: Up to one year

  7. Proportion of participants who wear the work wristband for a total of 1 week

    Feasibility will be defined as the proportion of participants who wear the work wristband for a total of 1 week. The feasibility rate will be summarized descriptively using point estimates and 95% confidence intervals.

    Time frame: Up to one year

  8. Chemical exposure measured by Fresh Air Clip wristband

    Acceptability will be measured in the follow-up survey using the question: "Overall, how acceptable did you find wearing the 'Fresh Air clip' wristband to measure chemical exposures in your daily life?" Participants who respond "No opinion," "Acceptable," or "Completely acceptable" will be categorized as finding the wristband acceptable. The acceptability rate will be summarized descriptively using point estimates and 95% confidence intervals.

    Time frame: Up to one year

07

Study locations

1 of 1 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Feb 2029, 28 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 28 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

Start moved once since we started tracking on Sep 25, 2026: Dec 2026 → Oct 2026, on Oct 20, 2026.

Primary completion moved twice since we started tracking on Sep 25, 2026: Jan 2028 → Feb 2029, last on Oct 30, 2026.

Completion moved once since we started tracking on Sep 25, 2026: Jan 2028 → Feb 2029, on Oct 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2026
First posted
Jul 8, 2026
StartActual
Oct 6, 2026was Dec 2026
Primary completionEst.
Feb 26, 2029was Jan 2028
CompletionEst.
Feb 26, 2029was Jan 2028
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Dec 28, 2026→Oct 6, 2026 (actual)
Oct 20, 2026
Primary completion
Jan 1, 2028→Feb 26, 2029
moved 2 times, Oct 20, 2026 – Oct 30, 2026
Study completion
Jan 1, 2028→Feb 26, 2029
Oct 20, 2026
Show all 2 updates
  1. Oct 30, 2026
    Primary completion Jan 26, 2029→Feb 26, 2029
  2. Oct 20, 2026
    Start date Dec 28, 2026→Oct 6, 2026 (now actual)
    Primary completion Jan 1, 2028→Jan 26, 2029
    Study completion Jan 1, 2028→Feb 26, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07690852
Responsible party
Sponsor
First posted
Jul 8, 2026
Start date
Oct 6, 2026
Primary completion
Feb 26, 2029 (estimated)
Completion
Feb 26, 2029 (estimated)
Last update
Oct 30, 2026

Study contacts

Stacy W Gray
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion